MannKind Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNKD research report →
Range $10 – $13
Price Chart
About the company
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U. S.
- CEO
- Michael E. Castagna
- IPO
- 2004
- Employees
- 592
- HQ
- Danbury, CA, US
Get TickerSpark's AI analysis on MNKD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.24B
- P/E
- -16.77
- Fwd P/E
- 78.75
- PEG
- 0.16
- P/S
- 3.07
- P/B
- -33.94
- EV/EBITDA
- 240.77
- Div Yield
- 0.00%
- Gross Margin
- 76.05%
- Op Margin
- -3.19%
- Net Margin
- -18.10%
- ROE
- 139.41%
- ROIC
- -1.98%
Latest fiscal year · YoY change
- Revenue
- $348.97M+22.2%
- Gross Profit
- $287.81M+37.8%
- Op Income
- $38.80M
- Net Income
- $5.86M-78.7%
- EPS
- $0.02-80.0%
- OCF Growth
- -57.1%
- FCF Growth
- -58.3%
- 52W High
- $6.51
- 52W Low
- $2.23
- 50D MA
- $3.57
- 200D MA
- $3.61
- Beta
- 1.09
- RSI (14)
- 52
- Avg Volume
- 3.95M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
MannKind said Q3 showed broad revenue growth, rapid adoption of Furoscix ReadyFlow and Afrezza pediatrics, and set up a return to profitability in Q4.· November 5, 2026
- Total Q3 revenue was $101.9 million, up 24% from $82.1 million a year ago; management said the company expects to return to profitability in Q4 on both GAAP and non-GAAP basis.
- Commercial product revenue was $45 million, nearly double last year, driven by Furoscix; Furoscix net revenue was $22.4 million and Afrezza was $19.3 million, up 5% year over year.
- Furoscix ReadyFlow adoption accelerated quickly: about 75% of shipments had converted by late October, and management said Q4 Furoscix sales should exceed the entire first half of 2026.
- Afrezza pediatric prescriptions grew strongly, with total prescriptions up about 17% sequentially and average monthly new-to-brand prescriptions up nearly 80% versus Q2.
- The pipeline and partner business remain important: nintedanib DPI Phase II is underway with data expected in the first half of 2028, and the company expects $15 million in ralinepag DPI milestones in 2027.
Third-quarter total revenue was $101.9 million, up 24% from $82.1 million in Q3 2025. Commercial product revenue was $45 million versus $22.3 million a year ago; Furoscix net revenue was $22.4 million and Afrezza net revenue was $19.3 million, up about 5% year over year. Royalty revenue was $37.5 million, up 12%, while collaboration and services revenue was $19.4 million versus $26.5 million last year. GAAP net loss was $23.2 million versus GAAP net income of $8.0 million in Q3 2025. For the first nine months, total revenue was $301.4 million, up 27% from $237.0 million, and management said it expects to return to profitability in Q4 on both GAAP and non-GAAP bases and to be profitable for full-year 2027.
Michael Castagna framed the quarter as the transition from delivering 2026 catalysts to executing on them. He said MannKind is now a diversified growth company with four FDA-approved products, no near-term IP cliffs, and three value engines: promoted commercial products, the United Therapeutics collaboration, and the Technosphere pipeline. His tone was upbeat and confident, emphasizing rapid Furoscix ReadyFlow conversion, strong pediatric Afrezza adoption, and long-term upside from nintedanib DPI and other pipeline/BD opportunities.
Chris Prentiss highlighted that Q3 revenue diversification continued, with commercial products becoming the largest source of revenue. He said Furoscix revenue was tempered by a roughly $3 million impact from the faster-than-expected ReadyFlow transition and limited channel inventory, but noted ReadyFlow has a meaningfully lower cost of goods, which should improve margins as conversion continues. He also said more than half of pediatric Afrezza prescriptions are already reimbursed, collaboration/services revenue for 2026 should be consistent with 2025, and 2026 included $11.6 million of CVR expense and $5.2 million of amortization in the quarter. He reiterated that 2026 was an investment year and said profitability should return in Q4 and on a full-year basis in 2027.
Analysts pressed on Furoscix growth, salesforce expansion, and whether management would separate OBI versus auto-injector reporting; management said growth was coming from new-to-brand patients and new prescribers, with about 56% prescription growth in the first six weeks versus the prior six weeks, and suggested a breakout likely would not be meaningful because most scripts should be on auto-injector by 2027. Questions on Afrezza focused on pediatric reimbursement and adult softness; management said approval rates are improving as payers update criteria, some adult underperformance was tied to field turnover and share-of-voice cuts, and they expect adult growth to recover while pediatrics continues to scale. Analysts also asked about the INFLO-2 timeline; management said the schedule depends on protocol approvals and possible FDA feedback on adding U.S. sites, with no interim analysis planned and readout still expected in the first half of 2028.
The call showed momentum in both commercial launches: Furoscix ReadyFlow is converting faster than expected, and Afrezza’s pediatric launch is already driving strong prescription growth and new prescriber adoption. Management also pointed to a durable royalty/mfg base from United Therapeutics, expected profitability in Q4 and 2027, and multiple near-term product and pipeline milestones that could add upside.
Management acknowledged Afrezza’s adult business has underperformed due to field turnover, lower share of voice, and competition from new insulin pumps, while pediatric reimbursement is still working through conversion to paid coverage. Furoscix still faces payer and access friction, especially around Medicare deductibles and IDN rollout timing, and the INFLO-2 program depends on protocol and FDA feedback that could shift its timing.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.5%
- Shares Outstanding
- 321.64M
- Float Shares
- 307.06M
of shares held by institutions
269 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 32.13M | ▲ 3.53M |
| Rubric Capital Management LP | 18.00M | ▲ 14.38M |
| Vanguard Group Inc | 17.88M | ▲ 250.29K |
| State Street Corp | 15.10M | ▼ 1.08M |
| Vanguard Capital Management LLC | 13.17M | ▲ 278.33K |
| Geode Capital Management, LLC | 8.05M | ▲ 105.52K |
| Wellington Management Group Llp | 7.84M | ▲ 4.56M |
| Frazier Life Sciences Management, L.P. | 6.60M | ▲ 700.00K |
| Deep Track Capital, LP | 6.00M | ▲ 6.00M |
| 180 Wealth Advisors, LLC | 4.99M | ▲ 26.75K |
| Fmr LLC | 4.54M | ▲ 438.83K |
| Tsp Capital Management Group, LLC | 4.18M | ▲ 207.85K |
Held by 223 ETFs
Biggest fund positions in MNKD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Friedman Michael A | other | 30,000 |
| Nov 17, 26 | Friedman Michael A | other | 8,109 |
| Nov 17, 26 | Friedman Michael A | other | 30,000 |
| Sep 25, 26 | Binder Steven B. | sell | 39,051 |
| Sep 10, 26 | Binder Steven B. | sell | 33,558 |
| Aug 7, 26 | Binder Steven B. | sell | 39,051 |
| Jul 15, 26 | Prentiss Christopher B | other | 11,572 |
| Jul 15, 26 | Prentiss Christopher B | other | 10,675 |
| Jul 15, 26 | Marasco Dominic | other | 3,623 |
| Jul 15, 26 | Tross Stuart A | other | 93,790 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MNKD coverage
Recent articles, reports, and earnings notes.
No research on MNKD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MNKD report →Should You Buy MannKind (MNKD) After Golden Cross?
zacks.com · Nov 19
MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectations
defenseworld.net · Nov 19
MannKind Sees Q4 Profit and Record Revenue as Drug Launches Gain Traction
marketbeat.com · Nov 18
MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectations
marketbeat.com · Nov 18
MannKind Corporation (MNKD) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
MannKind's ReadyFlow Launch Keeps The Bull Case Alive
seekingalpha.com · Nov 11
MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
MannKind Q3 Earnings Call Highlights
defenseworld.net · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.